| Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study. | |
| | |
MedLine Citation:
|
PMID: 22532232 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The association between use of oral bisphosphonate and cancer development in elder women is still uncertain, and previous studies showed controversial results. We used a nationwide, population-based database to explore the relationship between the use of alendronate, an oral bisphosphonate agent used for the treatment of osteoporosis, and the risk of all malignancies in women with osteoporosis and age over 55 years. In the study group, we included 6,906 women with osteoporosis (mean age, 73.4 ± 8.4 years) taking oral alendronate, who were selected from a 1,000,000 sample cohort dataset collected between January 1998 and December 2009. Another 20,697 age- and comorbidity-matched women (mean age, 73.5 ± 8.4 years) without bisphosphonates treatment were included in the control group. No subjects had any history of being diagnosed with cancer before inclusion. The log-rank test was performed to analyze the differences in accumulated cancer-free survival rates between these 2 groups. A Cox proportional-hazard model, adjusted for confounding factors, was used to evaluate the association between alendronate use and the development of all cancer events in postmenopausal women with osteoporosis. During the mean follow-up period of 4.8 years, 821 patients from the study group and 2,646 patients from the control group had new cancers. There was no significant difference in cancer incidence between alendronate users and controls (11.9% versus 12.8%, P = 0.054). The person-year incidence of newly-developed cancer in alendronate users and controls was 28.0 and 29.4 per 1,000 person-years, respectively. Alendronate use was not associated with increased risk of cancer development in women with osteoporosis. (adjusted hazard ratio: 1.05 [0.97-1.13], P = 0.237). However, due to the limited study size and underpowered results, further larger prospective studies or meta-analysis are suggested to further confirm our findings. © 2012 American Society for Bone and Mineral Research. |
| | |
Authors:
|
Chia-Hung Chiang; Chin-Chou Huang; Wan-Leong Chan; Po-Hsun Huang; Tzeng-Ji Chen; Chia-Min Chung; Shing-Jong Lin; Jaw-Wen Chen; Hsin-Bang Leu |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-24 |
Journal Detail:
|
Title: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research Volume: - ISSN: 1523-4681 ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-4-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8610640 Medline TA: J Bone Miner Res Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 American Society for Bone and Mineral Research. |
Affiliation:
|
Division of Cardiology, Department of Medicine, Zhudong Veterans Hospital, HsinChu, Taiwan; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Influence of estrogen replacement and aging on the expression of nerve growth factor in the urethra ...
Next Document: Prenatal diagnosis of fetal skeletal dysplasia with 3D CT.